Presenting data at the Bascom Palmer Eye Institute’s Angiogenesis, Exudation and Degeneration 2012 meeting in Miami, Florida, Dr. Pravin Dugel announced the results of a… Read More »CABERNET study fails to meet primary endpoint at 24 months
The UK, acting as the Reference Member State (RMS), and six other EU member states, are reported to have reached agreement for the approval of… Read More »Iluvien to be approved for chronic Diabetic Macular Edema (DME) by the UK, Austria, France, Germany, Italy, Portugal and Spain
QLT Inc., (NASDAQ: QLTI) a Canadian based biotechnology company headquartered in Vancouver, has announced that its oral synthetic retinoid product, QLT091001, has shown positive preliminary… Read More »Preliminary results from a Phase 1b trial of oral synthetic retinoid for the treatment of RP due to mutations in RPE65 and LRAT genes
Clinical research published in EURETINA’S journal, Ophthalmologica, has reported that treatment of diabetic macular edema with intravitreal bevacizumab and triamcinoclone combined or triamcinoclone only, showed… Read More »Korean study on bevacizumab and triamcinolclone treatment regimens in diabetic macular edema patients published in Ophthalmologica
LPath, Inc (OTCBB:LPTN, San Diego, USA), one of the world leaders in lipid based antibody therapeutics, has temporally suspended dosing in two clinical trials involving… Read More »LPath suspends dosing in two ophthalmic clinical trials following report on compliance issues from FDA
A first report on the 4-month follow up of two patients that received sub-retinal injections of human embryonic stem cell (hESC)-derived RPE has been published… Read More »Advanced Cell Technologies (ACT) provide first report on transplanting human embryonic stem cells into human patients
Quark Pharmaceuticals Inc., a clinical-stage pharmaceutical company based in Fremont, California, has announced interim data from an open-label, dose escalation Phase I trial in 38… Read More »Quark announces interim data from RNAi Phase I dosing for ocular neuro-protection
Diagnosing AMD as early as possible permits interventional management prior to the onset of any major structural or functional damage. A major goal of disease… Read More »Potential for psychophysical assessments to provide biomarker for AMD progression
The US Food & Drug Administration (FDA) has announced the approval of Eylea (aflibercept, formerly VEGF Trap Eye) for the treatment of neovascular age related… Read More »FDA Approves Eylea (aflibercept) for treatment of wet AMD
Results from a phase 1 pilot study investigating the use of high intensity focused ultrasound (“HIFU”) have shown both safety and efficacy in patients with… Read More »Clinical pilot study of ultrasound cyclocoagulation shows safety and efficacy in refractory glaucoma